厄洛替尼联合细胞因子诱导的杀伤细胞治疗晚期肺腺癌的临床观察

The therapy effects of CIK combining with erlotinib in the treatment of patients with advanced lung adenocarcinoma

目的探讨厄洛替尼（Erlotinib）联合细胞因子诱导的杀伤细胞（CIK）生物免疫治疗晚期肺腺癌的临床效果。方法选取2013年1月至2014年2月间经病理学或细胞学检查确诊的一线治疗失败的100例晚期（ⅢB期-Ⅳ期）肺腺癌患者，随机分为试验组和对照组，每组50例。试验组患者采用厄洛替尼和CIK生物免疫治疗，对照组患者采用厄洛替尼单药治疗，评价两组患者无进展生存（PFS）时间和不良反应发生情况。结果试验组和对照组患者的PFS分别为6．3个月（95％CI：6．0-6．6）和4．4个月（95％CI：4．2-4．6），差异有统计学意义（P〈0．05）。两组患者的不良反应主要为皮疹和腹泻。试验组患者在CIK输注过程中有2例出现胸闷，5例出现乏力，6例出现发热。结论厄洛替尼联合CIK治疗晚期肺腺癌是一种安全有效的方法。

Objective To evaluate the effects of cytokine induced killer （CIK） cells combining with erlotinib in the treatment of patients with advanced lung adenocarcinoma. Methods 100 patients with with advanced lung adenoeareinoma were enrolled into this study. All the patients underwent 4 cycles of platinum-based two-drug chemotherapy and achieved a status of progressive disease. The patients were ran- domized divided into experimental group and control group. Patients in the experimental group were treated with erlotinib and CIK cells, patients in the control group were treated erlotinib alone. The main end point was progression-free survival （PFS） , while the adverse reactions was the second end point. Results The PFS of experimental group and control group was 6. 3 months （95% CI：6. 0 -6.6） and 4.4 months （95% CI：4.2 -4. 6） , respectively, the difference was significant （P 〈 O. 05 ）. The untoward reactions of both groups were rashes and diarrhea. In the experimental group, chest distress was found in 2 patients, acratia in 5 patients, and fever in 6 patients during CIK infusion. Conclusion The therapy of which erlotinib com- bining with CIK cells is safe and effective in treating advanced lung adenoearcinoma.